Related Experiment Video

Updated: May 14, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Adaptive Immune Responses and HER2/neu Positive Breast Cancer

Eric D Mortenson1, Yang-Xin Fu

  • 1Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.

Current Pathobiology Reports
|February 20, 2013
PubMed

Insights

Trastuzumab therapy for HER2-positive breast cancer is enhanced by the adaptive immune system. This review explores the inflammatory response and immune system

Area of Science:

  • Oncology
  • Immunology
  • Breast Cancer Research

Background:

  • HER2/neu signaling drives tumorigenesis in a subset of breast cancer patients.
  • Anti-HER2/neu antibody therapy, like trastuzumab, has significantly improved outcomes for HER2-positive breast cancer.
  • Trastuzumab has been a cornerstone of HER2-positive breast cancer treatment for over two decades.

Purpose of the Study:

  • To review the role of the inflammatory response in HER2-positive breast cancer.
  • To emphasize the mechanisms of trastuzumab therapy, including its interaction with the immune system.
  • To highlight recent discoveries regarding anti-HER2/neu antibody's anti-tumor activity.

Main Methods:

  • Review of existing literature on HER2/neu signaling and trastuzumab therapy.
  • Analysis of molecular mechanisms underlying trastuzumab's anti-tumor effects.
  • Investigation into the role of the adaptive immune system in anti-HER2/neu therapy response.

Main Results:

  • Trastuzumab therapy's efficacy is linked to its blockade of HER2/neu signaling.
  • New mechanisms of trastuzumab's anti-tumor activity involve the initiation and requirement of the adaptive immune system.
  • The presence of anti-HER2/neu-initiated adaptive immunity supports immune-stimulating treatment strategies.

Conclusions:

  • The adaptive immune system plays a critical role in the efficacy of trastuzumab therapy for HER2-positive breast cancer.
  • Understanding the inflammatory response in HER2-positive breast cancer can lead to novel therapeutic approaches.
  • Targeting the immune system in conjunction with trastuzumab holds promise for improved treatment outcomes.
Keywords:
Adaptive immunityAntibody drug conjugatesAntibody therapiesBreast cancerCombination therapiesHER2/neuHerceptinImmune responsesImmunotherapyInflammationInnate immunityOncogenic signalingPathobiologyTrastuzumab

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...